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Introduction
Long-term exposure to traffic-related air pollu-
tion (TRAP) increases risk of cardio vascular 
events and mortality [Health Effects Institute 
(HEI) 2010]. High blood pressure (BP), a 
major risk factor worldwide, could mediate the 
cardio vascular effects of TRAP (Brook et al. 
2009). It has been hypothesized that long-term 
exposure to TRAP could raise BP chronically 
and increase the risk of hyper tension (Brook 
2007), thereby  contributing to the deleterious 
effects of air pollution on cardio vascular 
morbidity and mortality.
The evidence is very scarce so far. In two 
American studies with selected populations 
[elderly men (Schwartz et al. 2012) and black 
women (Coogan et al. 2012)], TRAP was 
linked to higher BP or hyper tension. In our 
previous study with a German population-
based cohort (Fuks et al. 2011), we found 
a positive association of ambient particulate 
matter (PM) with BP and an increased preva-
lence of hyper tension among those living near 
a major road. Long-term exposure to PM and 
gaseous air pollutants were associated with 
high BP and hyper tension in two large Asian 
cohorts (Chuang et al. 2011; Dong et al. 
2013). Long-term PM concentrations were 
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Background: Long-term exposure to air pollution has been hypothesized to elevate arterial blood 
pressure (BP). The existing evidence is scarce and country specific.
oBjectives: We investigated the cross-sectional association of long-term traffic-related air pollution with 
BP and prevalent hyper tension in European populations.
Methods: We analyzed 15 population-based cohorts, participating in the European Study of Cohorts 
for Air Pollution Effects (ESCAPE). We modeled residential exposure to particulate matter and nitrogen 
oxides with land use regression using a uniform protocol. We assessed traffic exposure with traffic indi-
cator variables. We analyzed systolic and diastolic BP in participants medicated and nonmedicated with 
BP-lowering medication (BPLM) separately, adjusting for personal and area-level risk factors and environ-
mental noise. Prevalent hyper tension was defined as ≥ 140 mmHg systolic BP, or ≥ 90 mmHg diastolic BP, 
or intake of BPLM. We combined cohort-specific results using random-effects meta-analysis.
results: In the main meta-analysis of 113,926 participants, traffic load on major roads within 100 m 
of the residence was associated with increased systolic and diastolic BP in nonmedicated participants 
[0.35 mmHg (95% CI: 0.02, 0.68) and 0.22 mmHg (95% CI: 0.04, 0.40) per 4,000,000 vehicles × m/day, 
respectively]. The estimated odds ratio (OR) for prevalent hyper tension was 1.05 (95% CI: 0.99, 1.11) per 
4,000,000 vehicles × m/day. Modeled air pollutants and BP were not clearly associated.
conclusions: In this first comprehensive meta-analysis of European population-based cohorts, we 
observed a weak positive association of high residential traffic exposure with BP in nonmedicated 
participants, and an elevated OR for prevalent hyper tension. The relationship of modeled air pollutants 
with BP was inconsistent.
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positively related to self-reported hyper tension 
among white American adults (Johnson and 
Parker 2009). However, not all findings are 
positive. In a large population-based Danish 
cohort of older adults, long-term exposure to 
nitrogen oxides (NOx; indicators of TRAP), 
was associated with decreased BP and lower 
prevalence of self-reported hyper tension 
(Sørensen et al. 2012).
In view of the sparse and partially contro-
versial evidence, we aimed to study the effects 
of long-term exposure to TRAP on BP and 
hyper tension in 15 European population-
based cohorts, using a uniform methodology. 
We investigated the cross-sectional association 
of particulate air pollutants, NOx, and traffic 
indicators with arterial BP as well as with 
the prevalence of hyper tension and intake 
of BP-lowering medication (BPLM). This 
work was performed as a part of the European 
Study of Cohorts for Air Pollution Effects 
(ESCAPE 2008).
Methods
General setting. We selected existing cohort 
studies of mortality and chronic diseases in 
Europe based on their potential to quantify 
relationships between long-term exposure 
and health response. Cohorts were eligible to 
participate in the analysis of BP and hyper-
tension if the following data were available: 
a) BP values, measured according to the World 
Health Organization (WHO) Multinational 
MONItoring of trends and determinants 
in CArdiovascular Diseases (MONICA) 
protocol (Hense et al. 1995) or a study-specific 
standard; b) information on BPLM use; and 
c) long-term residential TRAP concentrations 
at the residence, assessed with the ESCAPE 
land use regression (LUR) model.
A total of 15 study cohorts from nine 
countries were eligible to participate in this 
study: the national Finland Cardiovascular 
Risk study (FINRISK, Finland); the Danish 
Diet, Cancer and Health study (DCH, 
Denmark); the population-based Oslo 
Health Study (HUBRO, Norway); the 
Stockholm 60-year-olds cohort (60-year-
olds, Sweden); the Stockholm Diabetes 
Preventive Program (SDPP; Sweden); the 
Swedish National study of Aging and Care 
in Kungsholmen (SNAC-K; Sweden); the 
Swedish Twin Registry (TwinGene); the 
European Prospective Investigation into 
Cancer and Nutrition (EPIC) cohort in 
Umeå, Sweden (EPIC-Umeå); the EPIC 
Monitoring Project on Risk Factors for 
Chronic Diseases (EPIC-MORGEN; the 
Netherlands); the EPIC Prospect cohort 
(EPIC-Prospect; the Netherlands); the EPIC 
Oxford cohort (EPIC-Oxford; the United 
Kingdom); the Heinz Nixdorf Risk Factors, 
Evaluation of Coronary Calcification, and 
Lifestyle (Recall) study (HNR; Germany); the 
Cooperative Health Research in the Region 
of Augsburg (KORA; Germany); the Swiss 
Study on Air Pollution and Lung and Heart 
Disease In Adults (SAPALDIA; Switzerland); 
and Registre Gironí del Cor–Girona’s heart 
registry (REGICOR; Spain). Further details 
on each cohort is available in Supplemental 
Material, “Cohort-specific information, 
funding and acknowledgements,” pp. 3–9. 
Work in all cohorts was conducted in accor-
dance with the Declaration of Helsinki 
(World Medical Association 2013), and with 
all local ethical requirements.
Air pollution. Concentrations of PM, 
including particles with diameter ≤ 2.5 μm 
(PM2.5), ≤ 10 μm (PM10), > 2.5 to ≤ 10 μm 
(PMcoarse; calculated as PM10 minus PM2.5), 
PM2.5 absorbance (a marker for black carbon 
or soot), and NOx [nitrogen dioxide (NO2) 
and nitrogen monoxide (NO)] were modeled 
with LUR using a uniform ESCAPE procedure 
as described in Supplemental Material, “Land 
use regression model,” pp. 9–10, and elsewhere 
(Beelen et al. 2013; Eeftens et al. 2012). Briefly, 
annual averages of measured pollutant concen-
trations at the monitoring sites and predictor 
variables, derived from Europe-wide and local 
Geographic Information System databases 
were used to develop the study-specific LUR 
model and to predict concentrations at each 
participant’s address. To evaluate the impact of 
time-related changes in exposure, the predicted 
concentrations for PM10 and NO2 were back 
extrapolated to the time of the BP measure-
ment using data from routine monitoring sites 
(see Supplemental Material, “Extrapolation of 
exposure values back in time,” pp. 10–11).
Traffic indicators. We estimated the 
cumulative traffic exposure with two traffic 
indicators, selected a priori by the ESCAPE 
consortium to ensure comparability across all 
study areas: a) total traffic load on all major 
roads (defined as roads with traffic intensity 
> 5,000 vehicles/day) within a 100-m radius 
buffer around the residence, defined as the 
sum of traffic intensity multiplied by the 
length of major road fragments within the 
buffer (vehicles times meters per day); and 
b) traffic intensity on the nearest road (any 
road type; vehicles per day). Both indica-
tors were based on study area–specific road 
networks with traffic intensity data, based 
on both counted and modeled data. Time 
of assessment varied between study areas. 
We aimed to collect traffic data for different 
years including baseline, current, and data for 
years during relevant windows of exposure. 
For minor roads, traffic intensity data were 
missing in some local road networks. In 
these cases, missing data were imputed 
with a default value of 500 vehicles/day. 
Given that these roads were mainly minor 
roads, measurement error with regard to 
defining busy and nonbusy roads is likely 
small. Analyses of traffic indicator variables 
were adjusted for the predicted background 
 concentration of NO2.
Road traffic noise. We took the concurrent 
exposure to traffic noise into account. For that, 
we estimated 24-hr mean road traffic noise 
level (Lden) at the baseline address based on 
facade points of participants’ residences. Noise 
assessment was based on mandatory noise 
modeling according to the Directive 2002/49/
EC of the European Parliament and of the 
Council (European Commission 2002) (see 
Supplemental Material, “Noise assessment,” 
pp. 11–12).
Outcome assessment. BP was measured 
according to the WHO standard procedure 
(Hense et al. 1995) in three studies (KORA, 
HNR, and SAPALDIA), whereas other studies 
applied study-specific standardized procedures 
(Table 1). Automated oscillo metric devices 
(AODs) were used in nine cohorts: DCH, 
HUBRO, 60-year-olds, EPIC-MORGEN, 
EPIC-Prospect,  EPIC-Oxford, HNR, 
SAPALDIA, and REGICOR. Three cohorts 
used sphygmomanometers (SDPP, SNAC-K, 
and EPIC-Umeå), and two cohorts used 
either an AOD or a sphygmo manometer 
(TwinGene and KORA). In most studies, BP 
was measured on the right arm (nine studies), 
in a seated position (nine studies), and using 
different cuff sizes according to the upper 
arm circumference (all except FINRISK). BP 
was measured at least twice, with a minimum 
pause of 2 min, in all cohorts but SDPP 
and a part of EPIC-Oxford. In DCH, if 
the first measured BP value was considered 
abnormal, a new measurement was taken 
3 min later. The lowest BP measurement was 
recorded as final.
Intake of BPLM at baseline was assessed 
by questionnaire or interview and was avail-
able in 14 studies. Twelve cohorts had 
detailed information on the name of the drug, 
whereas two cohorts only had self-reported 
information on intake of any BPLM (see 
Supplemental Material, “Assessment of blood 
pressure lowering medication use,” p. 12). 
Hypertension was defined as systolic BP 
≥ 140 mmHg, diastolic BP ≥ 90 mmHg, or 
current intake of BPLM (Chobanian et al. 
2003). Intake of BPLM was examined as an 
additional outcome.
Statistical analyses in cohorts. We 
conducted the analyses in each cohort 
separately; no pooling of individual data 
was done. Cohort-specific analyses were 
performed in each study center according 
to a uniform statistical protocol, which 
is briefly described below (for more details, 
see Supplemental Material, “Cohort-specific 
analysis,” pp. 12–13). We used STATA 
versions 10–12 (StataCorp; http://www.stata.
com). BP readings were treated as contin-
uous outcomes; hyper tension and intake of 
Fuks et al.
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BPLM, as dichotomous outcomes. Analyses 
of systolic and diastolic BP were performed 
with linear regression. For analyses of BPLM 
intake and hyper tension, logistic regression 
was used. Linear regression model fit and 
assumptions were tested in each cohort (see 
Supplemental Material, “Cohort-specific 
analysis,” pp. 12–13). Results were presented 
for the fixed increments of exposures, harmo-
nized across all ESCAPE publications (see 
Supplemental Material, “Exposure increments 
in the analyses,” p. 11).
Correcting for the effect of antihypertensive 
medication. To account for the influence of 
BPLM intake on the level of measured BP, 
we assessed the effect of air pollution on 
BP in participants taking BPLM (“medi-
cated”) and in participants not taking 
BPLM (“non medicated”) separately. To 
increase power, we calculated results in 
subgroups of medicated and non medicated 
in the whole cohort, using an inter-
action term, exposure × BPLM intake. The 
analysis model was
BP = β0 + β1 × Exposure  
 + β2 × BPLM  
 + β3 × Exposure × BPLM 
 +…+ βk × Covariatek + ε. [1]
BPLM intake was coded as 0 (no medication) 
or 1 (medication). The effect of exposure on 
BP in medicated (BPLM = 1) participants was 
therefore estimated as
β1 × Exposure + β3 × Exposure × 1  
 = (β1 + β3) × Exposure. [2]
In non medicated participants (BPLM = 0),
β1 × Exposure + β3 × Exposure × 0  
= β1 × Exposure. [3]
We used the Z-test for interaction with 
pooled (meta-analysis) estimates in medicated 
and non medicated.
We also conducted a sensitivity analysis 
with normal right-censored regression to 
account for BPLM effect. With this method, 
BP in medicated participants was censored 
as right- censored (Tobin et al. 2005). The 
normal censored regression is fit in Equation 1, 
assuming that the underlying BP in the medi-
cated participants is equal or higher than the 
measured value under medication:
 BPunderlying ≥ BPmeasured if BPLM = 1 
 BPunderlying = BPmeasured if BPLM = 0. [4]
Covariates included in the analysis. We 
used harmonized definitions of covariates 
and adjustment sets. The adjustment sets 
were defined a priori using causal graphs 
(Glymour and Greenland 2008). The main 
model included age (years), sex (male, female), 
body mass index (BMI; kilograms per meter 
squared), smoking status (smoker, ex-smoker, 
nonsmoker), pack-years of smoking (total 
pack-years smoked), passive smoking (yes, no), 
alcohol consumption (never, 1–3 drinks/week, 
3–6 drinks/week, > 6 drinks/week; if wine 
was assessed separately, alcohol consump-
tion excluding wine was calculated), wine 
consumption (drinks per week; if avail-
able), physical activity (< once per month or 
< 1 hr/week, once per week or 1 hr/week, 
2–3 times/week or > 1 and < 3 hr/week, > 3 
times/week or > 3 hr/week), individual socio-
economic status [SES; defined as educational 
level (≤ primary school, ≤ secondary school or 
equivalent, ≥ university degree)] and economic 
activity (employed/self-employed, unem-
ployed, homemaker/housewife, retired).
In cases where a covariate was not 
 available, was of low quality, or contained 
> 10% missing values, the covariate was 
replaced by a similar covariate or excluded 
from the individual cohort-specific model. 
For example, instead of physical activity 
in categories (which was not available in 
REGICOR), a weekly leisure time physical 
activity variable was used.
Based on existing knowledge of possible 
nonlinear relationships for age, BMI, pack-
years of smoking, and wine consumption 
(where available), the corresponding terms 
were entered as linear and squared, centered 
on the mean.
Controlling for area-level effects. To adjust 
for potential clustering of the outcome on a 
small-scale spatial level, we included a random 
intercept for neighborhood in the mixed-
effects regression models. If area-level variables 
were available at different spatial scales, we 
used the scale corresponding to the spatial 
scale of the random intercept, which was 
chosen based on the Akaike information crite-
rion of the model. In addition, we controlled 
for potential confounding on the area level 
by including the information on neighbor-
hood SES as a covariate in the main model. If 
available, we used unemployment rate in the 
neighborhood, or, alternatively, welfare rate, 
average education level, or mean income.
Meta-analysis. The random effects meta-
analysis based on the DerSimonian and Laird 
(1986) method was performed. We defined 
the p-value of Cochrane’s Q-test < 0.05 or 
an I2 > 50% as an indication for hetero-
geneity (Higgins and Thompson 2002). 
Forest plots were produced using the package 
metafor (Viechtbauer 2010) in R version 
2.13.1 (R Project for Statistical Computing; 
http://www.r-project.org/).
As sensitivity analyses, we divided cohorts 
into groups by quality of BP measurement 
procedure and excluded studies one by one 
Table 1. BP measurement procedure in the participating cohorts.
Study Measurement period
WHO 
protocola Arm used
Different 
cuff sizes Body position Measurement device
Repeated 
measurements Final BP
FINRISK 1992, 1997, 2002, 2007 No Right No Sitting Manual mercury SM 2–3b Mean (1st–2nd)
DCH 1993–1997 No Right Yes Supine AOD 1–2c 1st
HUBRO 2000–2001 No Right Yes Sitting AOD 3 Mean (2nd–3rd)
60-year-olds 1997–1999 No Right Yes Supine AOD 2 Mean (1st–2nd)
SDPP 1992–1994, 1996–1998 No Either Yes Sitting Manual SM 1 1st
SNAC-K 2001–2004 No Left Yes Sitting, supine, standing Manual SM 4 2nd
TwinGene 2004–2008 No Right Yes Sitting AOD, manual SM 2 Mean
EPIC-Umeå 1992–1996 No Right Yes Sitting, supine Manual SM 2 Mean
EPIC-MORGEN 1993–1997 No Left Yes Supine AOD 2 Mean
EPIC-Prospect 1993–1997 No Left No Supine AOD 2 Mean
EPIC-Oxford 1993–2001 No Either Yes Sitting AOD 1–2d Last
HNR 2000–2003 Yes Right Yes Sitting AODe 3 Mean (2nd–3rd)
KORA 1994–1995, 1999–2001 Yes Right Yes Sitting Random-zero SM, AOD 3 Last
SAPALDIA 2001–2002 Yes Left Yes Sitting AOD 2 Mean
REGICOR 2003–2006 No Right Yes Sitting AOD 2f Last
SM, sphygmomanometer.
aHense et al. (1995). bTwo BP measurements were performed in 1992, 1997; three measurements in 2002, 2007. cIf the first measured BP value was considered abnormal, a new 
measurement was taken 3 min later; the lowest BP measurement was recorded as final. dBP was measured twice in a subset of 5,241 participants. eThe missing BP value with AOD 
was replaced with the value recorded with random-zero SM (in 34 participants, 0.7% of the sample). fIf the difference between the first and the second measurement was > 5 mmHg, a 
third measurement was performed.
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to investigate the impact of individual studies 
on the meta-estimate. We also conducted 
meta-regression using characteristics of 
population and exposure in the cohort as 
independent predictors. For further details, 
see Supplemental Material, “Sensitivity meta-
analysis and meta-regression,” pp. 13–15.
Results
We analyzed data from 15 cohorts in nine 
European countries, comprising 164,484 
individuals with information on exposure, 
outcome, and covariates (Table 2). Cohort-
specific baseline examinations were performed 
over a period that ranged from 1992 until 
2008. Two cohorts were excluded from 
the main meta-analysis: EPIC-Oxford, 
due to information on BPLM not being 
available, and DCH, due to a slightly 
different BP measurement method in 
hypertensive participants (“Methods”; see also 
Supplemental Material, Table S1). This left 
13 cohorts with 113,926 participants in the 
main meta-analysis of NOx and traffic load, 
and 12 cohorts with 90,852 participants in 
the main analysis of PM. All 15 cohorts were 
included in the extended meta-analysis.
Of the 113,926 participants in the main 
meta-analysis with NOx and traffic load in a 
100-m buffer, 14,943 participants (13.1%) 
were taking BPLM and 41,067 (36.0%) had 
hyper tension. Mean systolic BP in cohorts 
ranged from 120.8 mmHg to 142.7 mmHg; 
mean diastolic BP ranged from 75.0 mmHg 
to 84.5 mmHg (Table 2). Characteristics of 
participants included in the main analysis 
were similar to the extended sample (Table 2).
Mean pollutant concentrations increased 
from north to south across the studies 
(Table 3). Correlation between pollutant 
concentrations ranged from moderate 
(Pearson’s ρ = 0.5–0.7) to high (ρ > 0.7) 
(see Supplemental Material, Table S2). We 
observed a high correlation of PM measures, 
of PM with NOx, and of NO2 with NOx in 
most study areas. We observed moderate-to-
high correlations between pollutants, traffic 
indicators, and road traffic noise. The two 
traffic indicators were weakly (ρ = 0.3–0.5) to 
moderately correlated.
Associations with particulate air pollut-
ants. Modeled PM concentrations were not 
clearly associated with any of the studied 
outcomes in the single-pollutant models 
(Tables 4, 5 and Figure 1). We found a 
0.20-mmHg (95% CI: –0.76, 1.16) and a 
0.98-mmHg (95% CI: –0.35, 2.31) increase 
in systolic BP per 5-μg/m3 increase in PM2.5 
in non medicated and medicated participants, 
respectively. The pinteraction for PM2.5 × BPLM 
Table 2. Description of the study population in the cohorts included in the main and the extended meta-analysis. 
Study (country)
Participants 
(n)
Systolic BP 
(mean ± SD)
Diastolic BP 
(mean ± SD)
BPLM  
(%)
Hypertension 
(%)
Age 
(mean ± SD)
Men 
(%)
BMI [kg/m2  
(mean ± SD)]
Smokers 
(%)
FINRISK (Finland) 10,318 134.1 ± 19.3 80.7 ± 11.6 12.7 41.6 48.1 ± 13.2 47.0 26.4 ± 4.6 26.7
HUBRO (Norway) 16,200 130.3 ± 17.8 75.0 ± 11.2 11.8 32.0 47.8 ± 15.1 44.7 25.6 ± 4.1 25.4
60-year-olds (Sweden) 3,659 138.4 ± 21.8 84.5 ± 10.6 19.6 52.7 60.4 ± 0.1 47.1 26.8 ± 4.2 19.9
SDPP (Sweden) 7,535 122.8 ± 15.9 77.0 ± 10.0 5.8 24.0 47.1 ± 4.9 38.5 25.7 ± 4.0 26.1
SNAC-K (Sweden) 2,738 142.7 ± 20.2 81.3 ± 10.6 9.8 66.3 71.1 ± 9.5 41.7 25.7 ± 3.9 13.6
TwinGene (Sweden) 1,296 135.6 ± 18.8 83.8 ± 11.5 21.4 55.5 60.9 ± 6.0 39.7 25.2 ± 3.7 20.2
EPIC-Umeå (Sweden) 21,912 126.7 ± 17.2 78.6 ± 10.6 7.5 34.8 46.0 ± 10.2 47.8 25.0 ± 4.0 18.9
EPIC-MORGEN (Netherlands) 16,293 120.8 ± 16.3 76.8 ± 10.7 22.9 20.5 43.9 ± 10.9 45.2 25.2 ± 4.0 34.4
EPIC-Prospect (Netherlands) 16,434 132.5 ± 20.5 78.8 ± 10.8 20.4 43.4 57.7 ± 6.0 0 25.5 ± 4.1 22.2
HNR (Germany) 4,615 133.1 ± 20.8 81.4 ± 10.9 35.3 56.9 59.5 ± 7.8 49.9 27.9 ± 4.6 23.2
KORA (Germany) 7,501 131.0 ± 19.6 80.7 ± 10.9 18.5 41.0 50.5 ± 13.6 49.0 27.3 ± 4.6 24.4
SAPALDIA (Switzerland) 1,884a 126.1 ± 18.3 80.3 ± 10.5 19.3 37.3 53.3 ± 11.4 46.5 25.4 ± 4.2 27.1
REGICOR (Spain) 3,541 127.7 ± 19.9 78.4 ± 10.2 25.8 41.7 57.7 ± 12.3 45.2 27.0 ± 4.4 19.8
TOTALmain 113,926b 130.9 79.8 13.1 36.0 54.1 38.8 26.0 24.2
DCH (Denmark) 36,829 140.4 ± 20.6 83.4 ± 10.6 13.0 55.19 56.8 ± 4.4 47.1 26.0 ± 4.1 37.0
EPIC-Oxford (UK) 13,729 126.0 ± 19.1 77.1 ± 11.1 — 32.4 49.6 ± 11.6 22.8 24.5 ± 4.1 —
TOTALextended 164,484 131.2 79.8 12.0 40.0 54.0 39.3 25.9 25.0
Studies in the main meta-analysis are ordered from north to south.
aData on NOx and traffic indicators were available for all three sites of SAPALDIA: Basel, Geneva, Lugano (n = 1,884). PM exposure concentrations were available only for the Lugano 
site (n = 722). bn = 90,852 in the analysis of PM exposures. PM was not modeled in EPIC-Umeå and in two of three sites of SAPALDIA.
Table 3. Characteristics of the LUR model (leave-one-out cross-validation R2) and concentrations of long-term TRAP in cohorts (mean ± SD).
Study
R2 LUR validation PM2.5  
(μg/m3)
PM2.5 absorbance 
(10–5/m)
PMcoarse  
(μg/m3)
PM10  
(μg/m3)
NO2  
(μg/m3)
NOx  
(μg/m3)
Traffic load  
(106 vehicles × m/day)PM2.5 (%)a NO2 (%)b
FINRISK 53 75 7.7 ± 1.1 0.9 ± 0.2 6.6 ± 2.3 14.0 ± 3.1 15.3 ± 4.9 24.2 ± 8.8 0.6 ± 1.5
HUBRO 68 66 9.0 ± 1.3 1.2 ± 0.3 4.0 ± 2.0 13.5 ± 3.1 20.9 ± 7.9 38.3 ± 15.3 0.8 ± 1.9
60-year-olds 78c 83 7.3 ± 1.3 0.6 ± 0.2 7.4 ± 2.9 15.0 ± 3.8 10.8 ± 4.2 10.3 ± 3.6 0.5 ± 1.5
SDPP 78c 83 6.6 ± 1.2 0.5 ± 0.1 6.3 ± 2.4 13.7 ± 3.2 8.4 ± 1.7 14.4 ± 3.3 0.1 ± 0.4
SNAC-K 78c 83 7.9 ± 1.3 0.8 ± 0.2 8.5 ± 4.7 16.3 ± 6.0 17.4 ± 4.8 33.1 ± 12.3 2.2 ± 3.7
TwinGene 78c 83 7.3 ± 1.3 0.6 ± 0.2 7.2 ± 3.0 14.8 ± 4.0 10.7 ± 4.0 18.4 ± 8.9 0.6 ± 1.7
EPIC-Umeå — 83 — — — — 5.2 ± 2.4 8.7 ± 5.7 0.1 ± 0.4
EPIC-MORGEN 61 81 16.9 ± 0.6 1.4 ± 0.2 8.6 ± 1.1 25.4 ± 1.7 23.8 ± 7.0 36.4 ± 11.7 0.9 ± 2.0
EPIC-Prospect 61 81 16.8 ± 0.5 1.4 ± 0.2 8.5 ± 0.7 25.3 ± 1.2 26.7 ± 4.7 39.6 ± 10.6 0.7 ± 1.6
HNR 79 84 18.4 ± 1.1 1.6 ± 0.4 10.0 ± 1.8 27.8 ± 1.9 30.2 ± 4.9 50.8 ± 12.0 1.0 ± 2.2
KORA 62 67 13.6 ± 0.9 1.7 ± 0.2 6.2 ± 1.1 20.3 ± 2.4 18.7 ± 3.9 32.6 ± 7.4 0.4 ± 1.1
SAPALDIA 77d 58d, 82e 17.1 ± 1.4d 2.0 ± 0.4d 6.7 ± 1.2d 23.7 ± 2.2d 27.5 ± 6.4f 46.0 ± 13.8f 1.0 ± 1.8f
REGICOR 71 68 15.0 ± 1.7 2.3 ± 0.7 15.0 ± 2.4 32.0 ± 4.0 35.5 ± 14.2 63.2 ± 29.1 1.6 ± 2.3
TOTAL (main) 12.0 1.2 7.9 20.2 19.3 32.0 0.8
DCH 55 83 11.3 ± 0.9 1.15 ± 0.2 5.7 ± 1.0 17.1 ± 1.9 16.3 ± 7.0 26.6 ± 18.3 1.2 ± 2.3
EPIC-Oxford 77 87 9.7 ± 1.0 1.05 ± 0.2 6.4 ± 0.9 16.0 ± 2.0 22.9 ± 7.2 38.3 ± 14.0 0.4 ± 1.3
TOTAL (extended) 11.7 1.2 7.6 19.6 19.4 32.1 0.8
aEeftens et al. (2012). bBeelen et al. (2013). cCommon model was developed for the Stockholm cohorts: 60-year-olds, SDPP, SNAC-K, TwinGene. dOnly Lugano site of SAPALDIA. eOnly 
Basel and Geneva sites of SAPALDIA. fThree sites of SAPALDIA (Basel, Geneva, Lugano).
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intake was 0.25. Similar results were found 
for diastolic BP: an increase of 0.14 mmHg 
in non medicated (95% CI: –0.57, 0.85) 
and by 0.59 mmHg in medicated (95% CI: 
–0.19, 1.37) participants per 5-μg/m3 increase 
in PM2.5; the pinteraction was 0.26. The ORs for 
hyper tension and BPLM intake per 5-μg/m3 
of PM2.5 were 1.07 (95% CI: 0.95, 1.21) and 
1.06 (95% CI: 0.96, 1.17), respectively. 
Similarly, elevated, but non significant, esti-
mates were observed for PM2.5 absorbance, 
PMcoarse, and PM10. Results across studies 
were somewhat heterogeneous for PM2.5 and 
PMcoarse (Figure 1), displaying relatively large 
positive point estimates in some cohorts and 
inverse associations in others.
Associations with NOx. Modeled concen-
trations of NOx were not significantly asso-
ciated with any of the outcomes, although 
NO2 showed a weak inverse relationship with 
systolic BP in non medicated participants 
(–0.29; 95% CI: –0.70, 0.12) mmHg per 
10-μg/m3; the pinteraction with BPLM intake 
was 0.64). Results were similar for NOx 
(Tables 4, 5 and Figure 2). Significant hetero-
geneity was observed in the meta-analysis of 
NO2 and NOx with BP in non medicated 
participants and in the analysis with hyper-
tension (Figure 2).
Associations with traffic indicators. Traffic 
load in a 100-m buffer was associated with 
elevated BP in non medicated participants 
with an increase of 0.35 mmHg (95% CI: 
0.02, 0.68) systolic and 0.22 mmHg 
(95% CI: 0.04, 0.40) diastolic BP per 
4,000,000 vehicles × m/day, respectively, with 
no evidence for heterogeneity (Table 4 and 
Figure 2). The pinteraction values with BPLM 
intake were 0.14 and 0.15, respectively for 
systolic and diastolic BP. No association was 
found in medicated participants. The esti-
mated odds ratios (ORs) for hyper tension and 
BPLM intake were 1.05 (95% CI: 0.99, 1.11) 
and 1.04 (95% CI: 0.98, 1.10) per 4,000,000 
vehicles × m/day, respectively, with some 
evidence for hetero geneity for the outcome 
hyper tension (Table 5). In categori cal 
analyses of traffic load and BP, we found 
the highest effect estimates among the most 
exposed participants, although no consistent 
exposure– response relationship was observed 
(see Supplemental Material, Figure S1). 
Traffic intensity at the nearest road showed 
no association with the outcomes (Tables 4, 5 
and Figure 2).
Sensitivity analyses. Results with right-
censored regression (censoring by BPLM 
use) were similar to those in non medicated 
participants (Table 6). We observed a positive 
association of traffic load with systolic and 
Table 4. Adjusteda associations of TRAP and traffic indicators with BP, estimated with random-effects meta-analysis.
Outcome and exposure (increment)
Studies 
(n)
No BPLM BPLM intake
Changeb [mmHg (95% CI)] phet I 2 (%) Change [mmHg (95% CI)] phet I 2 (%)
Systolic BP
PM2.5 (5 μg/m3) 12c 0.20 (–0.76, 1.16) 0.09 38 0.98 (–0.35, 2.31) 0.49 0
PM2.5 absorbance (10–5/m) 12 0.07 (–0.46, 0.60) 0.42 3 –0.04 (–1.37, 1.29) 0.28 17
PMcoarse (5 μg/m3) 12 –0.09 (–0.76, 0.58) 0.01 58 0.30 (–0.44, 1.04) 0.59 0
PM10 (10 μg/m3) 12 0.09 (–0.60, 0.78) 0.10 36 0.44 (–0.68, 1.56) 0.36 9
NO2 (10 μg/m3) 13 –0.29 (–0.70, 0.12) 0.02 50 –0.14 (–0.77, 0.49) 0.26 18
NOx (20 μg/m3) 13 –0.08 (–0.47, 0.31) 0.03 48 0.04 (–0.43, 0.51) 0.61 0
Traffic load (4 × 106 vehicles × m/day) 13d 0.35 (0.02, 0.68) 0.35 9 –0.11 (–0.74, 0.52) 0.84 0
Traffic intensity (5,000 vehicles/day) 12e 0.08 (–0.06, 0.22) 0.86 0 0.11 (–0.22, 0.45) 0.73 0
Diastolic BP
PM2.5 (5 μg/m3) 12c 0.14 (–0.57, 0.85) 0.01 57 0.59 (–0.19, 1.37) 0.88 0
PM2.5 absorbance (10–5/m) 12 0.24 (–0.09, 0.57) 0.4 5 0.43 (–0.49, 1.35) 0.14 32
PMcoarse (5 μg/m3) 12 0.13 (–0.11, 0.37) 0.25 20 0.34 (–0.23, 0.91) 0.13 32
PM10 (10 μg/m3) 12 0.17 (–0.12, 0.46) 0.31 14 0.63 (–0.11, 1.37) 0.23 22
NO2 (10 μg/m3) 13 0.04 (–0.10, 0.18) 0.62 0 0.21 (–0.12, 0.54) 0.32 13
NOx (20 μg/m3) 13 0.09 (–0.05, 0.23) 0.62 0 0.32 (–0.01, 0.65) 0.30 14
Traffic load (4 × 106 vehicles × m/day) 13d 0.22 (0.04, 0.40) 0.72 0 –0.04 (–0.39, 0.31) 0.94 0
Traffic intensity (5,000 vehicles/day) 12e 0.08 (0.00, 0.16) 0.80 0 –0.04 (–0.30, 0.21) 0.22 22
I2 is a measure of heterogeneity between cohorts, and phet is a p-value for the Q-test of  heterogeneity.
aAdjusted for age, sex, BMI, smoking status, pack-years of smoking, passive smoking, alcohol consumption, physical activity, educational level, economic activity, neighborhood SES 
(including a random intercept for a neighborhood). bEstimated change in BP refers to the indicated exposure increment. cFINRISK, HUBRO, 60-year-olds, SDPP, SNAC-K, TwinGene, 
EPIC-MORGEN, EPIC-Prospect, HNR, KORA, SAPALDIA (Lugano site), REGICOR; n(total) = 91,574; n(non medicated) = 79,404; n(medicated) = 12,170. dFINRISK, HUBRO, 60-year-olds, 
SDPP, SNAC-K, TwinGene, EPIC-Umeå, EPIC-MORGEN, EPIC-Prospect, HNR, KORA, SAPALDIA, REGICOR; n(total) = 114,648; n(non medicated) = 99,705; n(medicated) = 14,943. 
eFINRISK, HUBRO, 60-year-olds, SDPP, SNAC-K, TwinGene, EPIC-Umeå, EPIC-MORGEN, EPIC-Prospect, KORA, SAPALDIA, REGICOR; n(total) = 110,033; n(non medicated) = 96,717; 
n(medicated) = 13,316.
Table 5. Adjusteda associations of TRAP and traffic indicators with prevalent hypertension and BPLM 
intake as outcomes, estimated with random-effects meta-analysis.
Outcome and exposure (increment) Studies (n) ORb (95% CI) phet I 2
Hypertension as outcome
PM2.5 (5 μg/m3) 12c 1.07 (0.95, 1.21) 0.13 33
PM2.5 absorbance (10–5/m) 12 1.05 (0.95, 1.16) 0.14 31
PMcoarse (5 μg/m3) 12 1.00 (0.94, 1.06) 0.07 40
PM10 (10 μg/m3) 12 1.01 (0.93, 1.09) 0.25 20
NO2 (10 μg/m3) 13 0.98 (0.92, 1.04) 0.01 55
NOx (20 μg/m3) 13 0.98 (0.92, 1.04) < 0.01 64
Traffic load (4 × 106 vehicles × m/day) 13d 1.05 (0.99, 1.11) 0.02 51
Traffic intensity (5,000 vehicles/day) 12e 1.02 (1.00, 1.04) 0.38 7
BPLM intake as outcome
PM2.5 (5 μg/m3) 12c 1.06 (0.96, 1.17) 0.85 0
PM2.5 absorbance (10–5/m) 12 1.08 (0.98, 1.19) 0.24 20
PMcoarse (5 μg/m3) 12 0.99 (0.93, 1.05) 0.63 0
PM10 (10 μg/m3) 12 0.98 (0.91, 1.06) 0.54 0
NO2 (10 μg/m3) 13 1.01 (0.97, 1.05) 0.30 14
NOx (20 μg/m3) 13 0.98 (0.94, 1.02) 0.60 0
Traffic load (4 × 106 vehicles × m/day) 13d 1.04 (0.98, 1.10) 0.12 33
Traffic intensity (5,000 vehicles/day) 12e 1.00 (0.98, 1.02) 0.76 0
I2 is a measure of heterogeneity between cohorts, and phet is a p-value for the Q-test of heterogeneity.
aAdjusted for age, sex, BMI, smoking status, pack-years of smoking, passive smoking, alcohol consumption, physical 
activity, educational level, economic activity, neighborhood SES (including a random intercept for a neighborhood). bOR 
for the indicated exposure increment. cFINRISK, HUBRO, 60-year-olds, SDPP, SNAC-K, TwinGene, EPIC-MORGEN, EPIC-
Prospect, HNR, KORA, SAPALDIA (Lugano site), REGICOR; n = 91,574. dFINRISK, HUBRO, 60-year-olds, SDPP, SNAC-K, 
TwinGene, EPIC-Umeå, EPIC-MORGEN, EPIC-Prospect, HNR, KORA, SAPALDIA, REGICOR; n = 114,648. eFINRISK, 
HUBRO, 60-year-olds, SDPP, SNAC-K, TwinGene, EPIC-Umeå, EPIC-MORGEN, EPIC-Prospect, KORA, SAPALDIA, 
REGICOR; n = 110,033.
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Figure 1. Cohort-specific and meta-analysis estimates of association of PM2.5 (A), absorbance PM2.5 (B), PMcoarse (C), and PM10 (D) with systolic BP and hyper-
tension. Results are presented per given increments. I2 is a measure of heterogeneity between cohorts, and phet is a p-value for the Q-test of heterogeneity.
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Figure 2. Cohort-specific and meta-analysis estimates of association of NO2 (A), NOx (B), traffic load at major road fragments (C), and traffic intensity at the 
nearest road (D) with systolic BP and hyper tension. Results are presented per given increments. I2 is a measure of heterogeneity between cohorts, and phet is a 
p-value for the Q-test of heterogeneity.
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diastolic BP. Findings for other pollutants 
were inconsistent.
We observed similar effects in the main 
analysis as compared with the extended 
analysis, which included DCH and EPIC-
Oxford (see  Supplemental  Mater ia l , 
Figure S2, for PM2.5, NO2, and traffic load 
and systolic BP; not shown for other pollut-
ants and diastolic BP; see also forest plots in 
main and extended meta-analysis with PM2.5 
and BP in Supplemental Material, Figure S3). 
When restricting the analysis to cohorts with 
at least three consecutive BP measurements, 
we observed a positive association of PM2.5 
with systolic BP in medicated participants 
and an increased estimate in non medicated 
participants (see Supplemental Material, 
Figure S2). No consistent differences by body 
position during measurement or by the BP 
recording device were observed.
Increasing the level of adjustment from 
the crude to the main model increased the 
effect estimates of PM2.5 with systolic BP (see 
Supplemental Material, Figure S4). Further 
adjustment with road traffic noise and 
season in the sensitivity models led to minor 
decreases in estimates with systolic BP (see 
Supplemental Material, Figure S5, for PM2.5, 
NO2 and traffic load; not shown for other 
pollutants). Exclusion of participants who had 
changed their address recently led to a minor 
decrease in the estimated change in systolic 
BP with PM2.5, increase with NOx and no 
difference with NO2 and traffic load (see 
Supplemental Material, Figure S5, for PM2.5, 
NO2, and traffic load; not shown for NOx). 
Back extrapolation of exposure estimates for 
PM10 and NO2 to the time of the baseline 
examination slightly increased the estimates 
for PM10 and NO2 (see Supplemental 
Material, Figure S5, for NO2; not shown for 
PM10). Traffic noise was associated with BP in 
only some of the cohorts (not shown).
In two-pollutant models including both 
PM2.5 and NO2, estimates were higher for 
PM2.5 and more negative for NO2 for systolic 
BP (see Supplemental Material, Table S3). 
This tendency remained after we excluded six 
studies with a high correlation of PM2.5 and 
NO2 (data not shown). No difference in esti-
mates was observed for diastolic BP (data not 
shown). A similar but less consistent pattern 
was observed for PM10 and PM2.5 absorbance 
with NO2 (data not shown).
In the meta-regression, mean age of the 
study participants was positively associated 
with the study-specific estimate for PM2.5 and 
NO2 in non medicated participants (p < 0.05; 
data not shown); no associations with other 
study characteristics (including leave-one-
out cross-validation R2 of the LUR model) 
were found.
Discussion
In this comprehensive study of up to 15 
European population-based cohort studies 
including up to 164,484 participants, high 
traffic load in a 100-m buffer around the resi-
dence was weakly associated with increased 
arterial BP in participants who were not 
taking BPLM, independent of background 
concentrations of NOx and road traffic 
noise levels. We also found a positive, yet 
imprecise, relationship of high traffic load 
with the odds for hyper tension and intake 
of BPLM. Modeled exposure to PM was not 
clearly related to BP, although point estimates 
were mostly elevated. We found positive asso-
ciations in the subgroup of studies with at 
least three consequent measurements of BP 
per participant. Modeled concentrations of 
NOx were not associated with BP, although 
we found a weak association between higher 
NO2 and lower BP. Results for PM2.5 
and NO2 were stronger when adjusted for 
each other.
Living close to a busy road has been 
positively associated with pulse pressure and 
inflammation markers (Rioux et al. 2010), 
impaired cardiac function (Van Hee et al. 
2009), narrower retinal arteriolar diameter 
(Adar et al. 2010), coronary heart disease 
prevalence and mortality (Gan et al. 2010; 
Hoffmann et al. 2006), and atherosclerosis 
progression (Hoffmann et al. 2007; Künzli 
et al. 2010). We previously reported an 
increased prevalence of hyper tension among 
participants living near a major road (Fuks 
et al. 2011). Our results for traffic load in 
non medicated participants were weak, 
although robust to adjustment for potential 
confounders such as background air pollution 
levels, personal cardio vascular risk factors, 
neighborhood SES, and road traffic noise. 
We think it is possible that the direct traffic 
emissions (which are not estimated with 
LUR, such as ultrafine particles) could be 
the reason for the observed associations. A 
relationship between ultrafine particles and 
acute changes in cardio vascular function—
such as heart rate variability, endothelial vaso-
motor function, and others—was reported 
in a recent review (Weichenthal 2012). On 
the other hand, we found no association of 
traffic intensity on the nearest road with any 
of the outcomes. This discordance may be 
explained by the difference between these two 
variables: whereas traffic intensity pertains 
to the closest road only (regardless of road 
type and of other high-traffic roads close by), 
traffic load takes into account all major roads 
within 100 m of the residence. As a result, the 
correlation between the two variables was low 
to moderate.
We observed positive point estimates of 
PM with BP in medicated participants and 
no association in non medicated participants. 
Results for long-term PM2.5 in medicated 
participants were generally in accordance with 
associations reported in earlier single-cohort 
studies in adults (Chuang et al. 2011; Coogan 
et al. 2012; Schwartz et al. 2012), although 
the confidence intervals were wider in our 
study despite its large size. The estimates for 
PM10 with BP in medicated participants 
were similar or even higher (for diastolic 
Table 6. Adjusteda associations of TRAP and traffic indicators with systolic and diastolic BP, estimated 
with right-censored regression and pooled using random-effects meta-analysis.
Outcome and exposure (increment) Studies (n)
Changeb  
[mmHg (95% CI)] phet I 2
Systolic BP
PM2.5 (5 μg/m3) 12c 0.13 (–0.80, 1.07) 0.14 31
PM2.5 absorbance (10–5/m) 12 0.03 (–0.94, 0.99) 0.06 42
PMcoarse (5 μg/m3) 12 –0.14 (–0.73, 0.45) 0.03 49
PM10 (10 μg/m3) 12 –0.06 (–0.57, 0.45) 0.37 8
NO2 (10 μg/m3) 13 –0.34 (–0.82, 0.13) 0.01 53
NOx (20 μg/m3) 13 –0.27 (–0.71, 0.17) 0.00 60
Traffic load (4 × 106 vehicles × m/day) 13d 0.36 (0.06, 0.67) 0.46 0
Traffic intensity (5,000 vehicles/day) 12e 0.05 (–0.10, 0.19) 0.72 0
Diastolic BP
PM2.5 (5 μg/m3) 12c 0.12 (–0.52, 0.76) 0.05 44
PM2.5 absorbance (10–5/m) 12 0.24 (–0.23, 0.72) 0.16 29
PMcoarse (5 μg/m3) 12 0.14 (–0.07, 0.36) 0.35 9
PM10 (10 μg/m3) 12 0.12 (–0.15, 0.40) 0.63 0
NO2 (10 μg/m3) 13 0.03 (–0.11, 0.18) 0.58 0
NOx (20 μg/m3) 13 0.06 (–0.07, 0.20) 0.55 0
Traffic load (4 × 106 vehicles × m/day) 13d 0.25 (0.08, 0.42) 0.56 0
Traffic intensity (5,000 vehicles/day) 12e 0.05 (–0.03, 0.13) 0.60 0
I2 is a measure of heterogeneity between cohorts, and phet is a p-value for the Q-test of heterogeneity.
aAdjusted for age, sex, BMI, smoking status, pack-years of smoking, passive smoking, alcohol consumption, physical 
activity, educational level, economic activity, neighborhood SES (including a random intercept for a neighborhood). 
bEffect estimate refers to the indicated exposure increment. cFINRISK, HUBRO, 60-year-olds, SDPP, SNAC-K, TwinGene, 
EPIC-MORGEN, EPIC-Prospect, HNR, KORA, SAPALDIA (Lugano site), REGICOR; n = 91,574. dFINRISK, HUBRO, 60-year-
olds, SDPP, SNAC-K, TwinGene, EPIC-Umeå, EPIC-MORGEN, EPIC-Prospect, HNR, KORA, SAPALDIA, REGICOR; 
n = 114,648. eFINRISK, HUBRO, 60-year-olds, SDPP, SNAC-K, TwinGene, EPIC-Umeå, EPIC-MORGEN, EPIC-Prospect, 
KORA, SAPALDIA, REGICOR; n = 110,033.
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BP) compared with those reported in a 
recent study from China (Dong et al. 2013). 
Restriction of the analysis to studies with 
at least three measurements of BP yielded 
higher estimates for PM in medicated partici-
pants. This finding points to the necessity 
of reducing the outcome measurement error 
by repeated and standardized assessments of 
BP. The observed heterogeneity of the results 
might also be explained in part by different 
constituents contributing to the complex 
PM mixture across the European study 
areas. Recently, Wu et al. (2013) reported 
positive and inverse short-term associations of 
different PM constituents with BP.
We found a weak association between 
higher NO2 and lower systolic BP in 
non medicated participants, which, although 
not statistically significant, was robust to the 
inclusion of traffic noise and to adjustment for 
temporal changes by using back- extrapolated 
concentrations. When we included both 
PM2.5 and NO2 in a two-pollutant model for 
systolic BP, the positive estimate for PM2.5 
increased in non medicated participants, 
whereas the negative estimate for NO2 further 
decreased. An NO2-related BP decrease has 
been shown before, in a large Danish study 
using a different exposure model (Sørensen 
et al. 2012); however, coherent biological 
explanations are still missing.
We found partially different results in 
the groups by BPLM intake. Although traffic 
load was associated with BP in non medicated 
participants, PM was weakly related to BP only 
in medicated participants. The proportion of 
medicated participants differed greatly among 
the studies. A medication-induced decrease in 
BP may mask any influences of environmental 
factors, especially if the prescription of BPLM 
is in part related to environmentally induced 
high BP. On the other hand, participants 
not using BPLM may represent a less suscep-
tible population group, especially in older 
cohorts. It is, therefore, possible that results in 
non medicated participants may underestimate 
the true effect in the population.
The suggested biological mechanisms for 
cardio vascular effects of particulate TRAP 
include the elicitation of local and systemic 
inflammation and oxidative stress, autonomic 
imbalance, and endothelial dysfunction 
(Brook 2007; Brook et al. 2009). Results 
from animal hyper tension models have shown 
that PM2.5 could potentiate hyper tension by 
modulating the sensitivity to pressure stimuli 
(Sun et al. 2008).
The estimated change in BP after exposure 
to TRAP is rather small. However, even small 
changes of arterial BP can be of high public 
health importance. Reducing the systolic BP 
by only 2 mm leads to a reduction in stroke 
mortality of 5%, in coronary heart disease 
mortality of 4%, and in total mortality of 3% 
(Whelton et al. 2002). A 2-mmHg reduction 
in diastolic BP has been linked to a 6% 
decrease in the risk of coronary heart disease 
and a 15% decrease in the risk of stroke and 
transient ischemic attack (Cook et al. 1995).
Assessing exposure with models always 
implies imprecision (i.e., misclassification), 
which might have masked or weakened true 
associations. In addition, TRAP modeling 
with the ESCAPE protocol was performed 
on average 5–10 years after BP had been 
measured. Personal exposure misclassification 
will likely increase over longer time periods, 
and possibly mask the small effects. However, 
in our meta-regression, we did not find any 
influence of the time period between exposure 
and outcome assessment on the meta-analysis 
estimate. In addition, LUR models have been 
recognized as reliable estimators of spatial 
air pollution gradients for decades (Eeftens 
et al. 2011).
Some of the estimated ORs for hyper-
tension and BPLM intake were as high as 
1.08 in the present study. However, given 
the relatively high prevalence rates of BPLM 
intake of 35–66% across our cohorts, this 
prevalence OR likely overstates the magni-
tude of the effect on the prevalence ratio.
One limitation of our study is that BPLM 
are sometimes prescribed for conditions 
other than hyper tension. For example, beta 
blockers are also used for managing cardiac 
arrhythmias. To overcome this limitation, we 
analyzed several related outcomes, including 
measured BP only, intake of BPLM only, 
and hyper tension as a composite outcome. 
Extended outcome definitions, such as 
prehyper tension, could be added to future 
analyses because prehyper tension has been 
associated with cardio vascular and cerebro-
vascular disease (Erbel et al. 2012). A more 
reliable investigation of the air pollution effect 
in participants using BPLM will be possible in 
cohorts with repeated prospective assessment 
of BP and BPLM.
This is by far the largest study to date to 
investigate the effect of long-term exposure 
to TRAP on arterial BP and hyper tension. 
We included up to 164,484 participants from 
large population-based cohorts in Europe. 
We used the same protocol for dedicated 
air pollution measurement campaigns and 
for LUR modeling across all study areas, 
underwent great efforts to assess and define 
outcome variables and covariates in compa-
rable ways, and applied identical statistical 
analysis procedures that accounted for BPLM 
intake in each cohort. We used data from 
all ESCAPE cohorts where BP data were 
available and of satisfactory quality, regard-
less of whether any effects of air pollution on 
BP had been investigated or shown in these 
cohorts previously, therefore diminishing the 
 probability of publication bias.
Conclusions
This is the largest study on the effect of air 
pollution on BP and the only meta-analysis 
to date. Using 15 European population-based 
cohorts we observed a weak positive associa-
tion of high residential traffic exposure with 
arterial BP in participants without BPLM 
intake and an elevated OR for prevalent 
hyper tension. The relationship of modeled 
air pollutants with BP was inconsistent, 
although positive relationships with BP in 
medicated participants and in the subgroup of 
studies with higher quality BP measurements 
were observed. Because of the importance of 
arterial BP and hyper tension as the major risk 
factors for premature mortality worldwide, 
these findings have large public health impli-
cations and point to the necessity of refined 
analyses using information on air pollution 
components, personal characteristics that 
may convey differential susceptibility, and 
high-quality outcome assessments.
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